References
1. Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. 2018;379(9):856-868.
2. Jouenne F, Chevret S, Bugnet E, et al. Genetic landscape of adult Langerhans cell histiocytosis with lung involvement. Eur Respir J. 2020;55(2):1901190.
3. Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019;37(31):2857-2865.
4. Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis.Blood. 2020;135(16):1319-1331.
5. Lee LH, Gasilina A, Roychoudhury J, et al. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes. JCI Insight.2017;2(3):e89473.
6. Azorsa DO, Lee DW, Wai DH, et al. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.Pediatr Blood Cancer. 2018;65(9):e27237.
7. Héritier S, Barkaoui MA, Miron J, et al. Incidence and risk factors for clinical neurodegenerative Langerhans cell histiocytosis: a longitudinal cohort study. Br J Haematol. 2018;183(4):608-617.
8. McClain KL, Picarsic J, Chakraborty R, et al. CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions. Cancer.2018;124(12):2607-2620.
9. Eckstein OS, Visser J, Rodriguez-Galindo C, Allen CE, Group N-LS. Clinical responses and persistent BRAF V600E(+) blood cells in children with LCH treated with MAPK pathway inhibition Blood 2019; 15:1691-1694.
10. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature.2019;567(7749):521-524.
11. Chen SH, Zhang Y, Van Horn RD, et al. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120. Cancer Discov. 2016;6(3):300-315.
12. Rollins BJ. Biology and Genomics of LCH and Related Disorders. In: Abla O, Janka G, eds. Histiocytic disorders. Cham, Switzerland: Springer; 2018:53-71.